You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

Article metrics

Article menu

Download PDFPDF

XML
Correction
Correction: Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

 

Online download statistics by month:

Online download statistics by month: February 2021 to March 2024

AbstractFullPdf
Feb 2021012026
Mar 202105311
Apr 202106013
May 20210435
Jun 20210629
Jul 202105611
Aug 202105410
Sep 20210345
Oct 202105520
Nov 202104817
Dec 20210473
Jan 20220254
Feb 20220134
Mar 20220153
Apr 20220185
May 202202412
Jun 20220275
Jul 20220215
Aug 20220352
Sep 20220239
Oct 20220226
Nov 20220167
Dec 2022052
Jan 202301713
Feb 20230272
Mar 2023094
Apr 2023054
May 2023043
Jun 2023061
Jul 202301111
Aug 2023043
Sep 2023072
Oct 2023082
Nov 20230164
Dec 2023091
Jan 20240205
Feb 20240224
Mar 202401139
Total01052292